breast cancer
Conditions
Interventions
Experimental Group:trastuzumab(Zercepac)
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Female or male patients aged 18 and above; 2. HER2 positive (IHC 3+ and / or FISH+); 3. Patients who agree to voluntarily receive trastuzumab alone/in combination with other adjuvant therapies; 4. ECOG score is 0-1; 5. There is no serious heart, liver and kidney disease, liver and kidney function is normal in the past three weeks, CBC is normal, ECG is basically normal, and LVEF >= 50%; 6. Patients who agreed to participate in the study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant woman or suckling period woman; 2. Expected survival is less than or equal to 3 months; 3. Mental illness or other conditions affecting patient compliance; 4. Congestive heart failure, or unstable angina pectoris, history of myocardial infarction within 6 months prior to study enrollment, uncontrolled hypertension considered by researchers, and high-risk, uncontrolled arrhythmias; 5. Uncontrolled acute infection; 6. Patients with allergic constitution and known/suspected allergy to any study drug; 7. Patients who participated in other intervention studies within 8 weeks; 8. The researchers consider that it is not suitable to participate in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Disease-free survival;Complete pathologic remission rate; | — |
Countries
China
Contacts
Public ContactPan Meifang
First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed